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Supportive careAbstract Background: Cabazitaxel/prednisone has been shown to prolong survival versus
mitoxantrone/prednisone in patients with metastatic castration-resistant prostate cancer
(mCRPC) that has progressed during or after docetaxel. Subsequently, compassionate-use
programmes (CUPs) and expanded-access programmes (EAPs) were established worldwide,
allowing access to cabazitaxel before its commercial availability. Preliminary results of the
European CUP/EAP, focusing on the elderly population (aged P70 years), are reported.
Patients and methods: Enrolled patients with progressive mCRPC received cabazitaxel
(25 mg/m2) plus 10 mg oral prednisone/prednisolone every 3 weeks until disease progression,
death, unacceptable toxicity or physician/patient decision. Safety was analysed by age group
(<70, 70–74 and P75 years). The inﬂuence of selected variables on grade P3 neutropenia
and/or neutropenic complications was analysed in multivariate analysis.
Results: 746 men were enrolled (<70 years, n = 421; 70–74, n = 180, P75 years, n = 145).
Number of cabazitaxel cycles, dose reductions for any cause, dose delays possibly related to49 241
A. Heidenreich et al. / European Journal of Cancer 50 (2014) 1090–1099 1091cabazitaxel adverse events, and tolerability were similar in the three age groups. Prophylactic
granulocyte colony-stimulating factor (G-CSF) use was more common in men aged
P70 years. In multivariate analysis, age P75 years, treatment cycle 1, and neutrophil count
<4000/mm3 before cabazitaxel injection were associated with increased risk of developing
grade P3 neutropenia and/or neutropenic complications. Prophylactic use of G-CSF at a
given cycle signiﬁcantly reduced this risk by 30% (odds ratio 0.70, p = 0.04).
Conclusion: The results suggest that cabazitaxel has a manageable safety proﬁle in everyday
clinical practice. Prophylactic use of G-CSF, especially at cycle 1 and in men agedP75 years,
is important and improves tolerability in senior adults treated with cabazitaxel.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
The past 4 years have seen signiﬁcant advances in the
management of metastatic castration-resistant prostate
cancer (mCRPC), with ﬁve novel therapies (abiraterone,
cabazitaxel, enzalutamide, radium-223, and sipuleucel-
T) demonstrating a survival beneﬁt in phase III clinical
trials [1–5].
Taxanes have an important role in this broad arma-
mentarium. Their anti-tumour activity has been shown
to promote assembly and stabilisation of microtubules,
blocking tumour cell division [6], and inhibiting tumour
cell traﬃcking, including nuclear translocation of the
androgen receptor, a key driver of prostate cancer
growth [7,8]. In 2004, the results of two pivotal phase
III studies (TAX 327 and SWOG 99-16) demonstrated,
for the ﬁrst time, a signiﬁcant improvement in overall
survival (OS) with docetaxel/prednisone and docetaxel/
estramustine compared with mitoxantrone/prednisone
[9–11]. Moreover, 19% of patients treated in TAX 327
and receiving docetaxel every 3 weeks (q3w) survived
for at least 3 years, versus only 14% with mitoxantrone
[11]. Based on these results, docetaxel plus prednisone
became the standard of care for mCRPC, recommended
by many international guidelines [12–17].
Cabazitaxel is a next generation taxane, selected for
clinical development based on its ability to overcome
docetaxel resistance and its ability to cross the blood–
brain barrier in preclinical animal models [18–20]. In
the phase III TROPIC trial, median survival was
15.1 months (95% conﬁdence interval [CI] 14.1–16.3)
with cabazitaxel/prednisone, and 12.7 months (95% CI
11.6–13.7) with mitoxantrone/prednisone [1]. Updated
results showed a long-term survival beneﬁt, with almost
twice as many patients alive at 2 years with cabazitaxel
compared with the active control arm mitoxantrone
(15.9% versus 8.2%; odds ratio [OR] 2.11; 95% CI
1.33–3.33) [21].
Cabazitaxel is now considered an eﬀective treatment
option for mCRPC for patients progressing during or
after docetaxel [12,13,15,16]. In TROPIC, however, cab-
azitaxel was associated with some clinically important
adverse events (AEs)—mainly an increased risk of gradeP3 febrile neutropenia (cabazitaxel 8% versus mitoxan-
trone 1%) and gradeP3 diarrhoea (cabazitaxel 6% ver-
sus mitoxantrone <1%) [1]. Overall, 5% of patients in
the cabazitaxel group and 2% of those in the mitoxan-
trone group died within 30 days of the last infusion—
the most frequent cause of death in the cabazitaxel
group was neutropenia and its clinical consequences.
This toxicity might have, at least in part, been because
patients were heavily pretreated and had very advanced
disease, prophylactic G-CSF at the ﬁrst cabazitaxel cycle
was not allowed (it was only allowed at ﬁrst occurrence
of either neutropenia lasting P7 days or neutropenia
complicated by fever or infection) and because in this
worldwide study, some centres lacked expertise in pro-
active management of AEs [22]. The crucial role of ade-
quate patient care was highlighted by a post hoc analysis
limited to French TROPIC centres (90 patients in total)
where proactive management of side-eﬀects was
required [23]. In this sub-study, the discontinuation rate
due to AEs with cabazitaxel was lower than in the global
TROPIC population (11% versus 18%) and there was no
death due to toxicity, resulting in a greater OS beneﬁt
versus mitoxantrone (18.0 months versus 14.3 months).
The TROPIC results led to the establishment of com-
passionate-use programmes (CUPs) and early-access
programmes (EAPs) in 30 countries worldwide, allowing
access to the drug before its commercial availability. An
awareness programme for physicians and nurses on the
pro-active management of AEs related to cabazitaxel
was implemented in each centre. Results from the Ger-
man CUP and the Italian EAP have already been pub-
lished [24,25]. Compared to TROPIC, there was a
consistently lower rate of febrile neutropenia (Germany
1.8%; Italy 5% versus 8% in TROPIC) and grade P3
diarrhoea (Germany 0.9%; Italy 2.8% versus 6% in TRO-
PIC) [1,24,25], demonstrating the beneﬁts of pro-active
measures to reduce the incidence and severity of cabazit-
axel-related AEs. In this paper, we report the preliminary
safety results of the European CUPs/EAPs. In the inter-
est of patients, the safety analysis focuses particularly on
the senior adult patients (aged 70–74 and P75 years) as
this population is at increased risk of chemotherapy-
induced AEs due to associated comorbidities [26].
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The European CUP/EAP allowed patients with
mCRPC that had progressed during or after docetaxel
to access cabazitaxel before its commercial availability
and aimed to further document the safety proﬁle of cab-
azitaxel. In agreement with national regulations, no eﬃ-
cacy data were collected.
Men with mCRPC with documented disease progres-
sion during or after a docetaxel-containing regimen and
an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0–2 were eligible. Additional inclusion
criteria were signed informed consent; life expectancy of
P3 months; surgical or ongoing medical castration (tes-
tosterone serum levels <50 ng/dl); and adequate bone
marrow, liver and renal function (neutrophils >1500/
mm3; haemoglobin >10 g/dl; platelets > 100  109/l; bil-
irubin <1  upper limit of normal [ULN]; aspartate
transaminase <1.5  ULN; alanine aminotransferase
<1.5  ULN; creatinine <1.5  ULN, or creatinine
clearance >60 ml/min if creatinine 1.0–1.5  ULN).
Ineligibility criteria included prior radiotherapy to
P40% of bone marrow; prior radionuclide therapy with
samarium-153 or P-32within 8 weeks of enrolment orwith
strontium-89 or radium-223within 12 weeks of enrolment;
and prior surgery, radiation or chemotherapy within
4 weeks of enrolment. Patients were ineligible if they had
active gradeP2 peripheral neuropathy or gradeP2 sto-
matitis; active infection requiring systemic antibiotic or
anti-fungal medication; second primary cancer in the pre-
vious 5 years (except superﬁcial non-melanoma skin can-
cer); and known brain or leptomeningeal involvement.
Patients with hypersensitivity to docetaxel, polysorbate-
80-containing drugs, prednisone or prednisolone, or an
uncontrolled severe illness or medical condition (including
uncontrolled cardiac arrhythmias, angina pectoris, hyper-
tension, diabetes mellitus or a history of congestive heart
failure or myocardial infarction) within the last 6 months
were also excluded.A 1-weekwashout periodwas required
for potent inducers of cytochrome P450 3A4/5.2.1. Treatment modalities and follow-up
Cabazitaxel (25 mg/m2 q3w) was provided free of
charge and administered as a 1-h intravenous infusion,
in combination with oral prednisone/prednisolone
(10 mg daily). Patients were treated until disease pro-
gression, death, unacceptable toxicity, physician’s or
patient’s decision to stop treatment, or commercial
availability of cabazitaxel.
Patients were followed during treatment and for
30 days after last cabazitaxel administration. Most
recent haematology (neutrophils, platelets, haemoglo-
bin) before each cabazitaxel injection was collected in
the case report form. Prophylactic and therapeutic use
of G-CSF according to the American Society of ClinicalOncology (ASCO) and European Organisation for
Research and Treatment of Cancer (EORTC) guidelines
was recommended, including from cycle 1 [14,27] and an
awareness programme for physicians and nurses on the
pro-active management of AEs related to cabazitaxel
was implemented.2.2. Statistical analysis
Statistical analyses were mainly descriptive. The
inﬂuence of selected variables (age [<70 versus 70–74
versusP75], treatment cycle [1 versus >1], median time
since diagnosis, presence or absence of visceral metasta-
ses, median number of prior docetaxel cycles [P10 ver-
sus <10], ECOG performance status, G-CSF
prophylactic use at a given cycle and neutrophil count
[<4000 versusP4000/mm3] before cabazitaxel injection)
on the occurrence of gradeP3 neutropenia and/or neu-
tropenic complications was analysed using a General-
ised Estimating Equations (GEE) model which adjusts
for the clustering of treatment cycles within a patient
[28]. This model oﬀers the ability to reassess the risk
of grade P3 neutropenia and/or neutropenic complica-
tions before each chemotherapy cycle. Variables with a p
value 60.25 were kept in the ﬁnal model. A multivariate
logistic GEE analysis with backward selection proce-
dure was then applied based on GICu criterion.3. Results
3.1. Population characteristics
Up to 31 August 2011, 746 patients from 20 Euro-
pean countries were enrolled in the CUP/EAP. At base-
line, 421 were aged <70 years, 180 were aged 70–
74 years and 145 were aged P75 years. Disease charac-
teristics of the age groups, listed in Table 1, were similar
in the three age groups, with expected diﬀerences in time
since ﬁrst diagnosis and diagnosis of metastatic disease.
Around 90% had an ECOG performance status of 0–1.
The types of progression prior to cabazitaxel initia-
tion are listed in Table 1. Approximately two-thirds of
patients demonstrated clinical or radiological progres-
sion and one-third of patients demonstrated biochemical
progression only. Metastases were mainly located in the
bone (92%), lymph nodes (regional 32%, distant 30%)
and visceral/soft tissues (28%). Overall, 16% of patients
progressed during docetaxel therapy and 84% after
discontinuation of docetaxel (within a median of
4.2 months).3.2. Cabazitaxel exposure in patients having completed
treatment or withdrawing from the study for any reason
Cabazitaxel exposure was analysed in 426 patients
who ended treatment (Table 2). Reasons for ending of
Table 1
Characteristics of patients <70, 70–74 and P75 years at baseline.
<70 years
(n = 421)
70–74 years
(n = 180)
P75 years
(n = 145)
Total (n = 746)
Mean age (years) [SD] 62.5 [5.2] 71.9 [1.5] 77.8 [2.6] 67.7 [7.5]
ECOG performance status (%)
0 40.4 40.6 31.3 38.7
1 50.4 48.3 55.6 50.9
2 9.3 11.1 13.2 10.5
Androgen deprivation (%)
Medical 89.3 87.2 87.6 88.5
Surgical 10.7 12.8 12.4 11.5
Median time since diagnosis of PCa (months) [Q1–Q3] 50.6 [30.5–74.7] 73.8 [46.6–110.2] 82.2 [46.5–121.3] 58.5 [36.9–93.2]
Median time since diagnosis of mCRPC (months) [Q1–Q3] 20.6 [12.8–33.7] 21.0 [13.9–39.5] 22.8 [15.2–38.1] 21.0 [13.5–36.4]
Median time from last docetaxel dosea (months) [Q1–Q3] 4.9 [2.4–10.2] 5.6 [2.5–10.9] 6.5 [2.3–10.9] 5.3 [2.4–10.6]
Time to progression since last docetaxel dosea
During last docetaxel therapy (%) 18.5 11.8 16.0 16.4
<6 months since last docetaxel dose (%) 51.1 54.5 44.4 50.6
P6 months since last docetaxel dose (%) 30.5 33.7 39.6 33.0
Median time from last docetaxel dosea to ﬁrst cabazitaxel
dose (months) [Q1–Q3]
5.2 [2.7–10.4] 6.0 [2.8–11.7] 6.7 [2.6–11.4] 5.6 [2.7–10.8]
Metastatic sites (%)
Bone 91.9 94.4 87.6 91.7
Regional lymph nodes 32.1 29.4 32.9 31.6
Distant lymph nodes 27.8 35.0 30.6 30.1
Visceral 24.9 23.4 28.9 25.3
Type of progression prior to cabazitaxel initiation (%)
Bone scan 39.7 45.0 34.5 39.9
Clinical progression (worsening of symptoms or cancer
pain)
34.2 24.4 24.8 30.0
PSA progression only 30.2 29.4 33.1 30.6
Measurable lesions 20.9 30.6 26.9 24.4
Median number of cycles during last docetaxel line [Q1–Q3] 9.0 [6.0–10.0] 8.0 [6.0–10.0] 8.0 [6.0–12.0] 8.0 [6.0–10.0]
Cumulative doses of previous docetaxel treatment (mg/m2)
Mean [SD] 748.2 [438.5] 684.3 [502.9] 789.7 [610.1] 740.7 [492.7]
Median [Q1–Q3] 675.0 [450.0–900.0] 600.0 [450.0–805.0] 600.0 [450.0–840.0] 600.0 [450.0–840.0]
Previous docetaxel dose >900 mg/m2 (%) 26.2 21.1 24.3 24.6
ECOG = Eastern Cooperative Oncology Group; mCRPC = metastatic castration-resistant prostate cancer; PCa = prostate cancer; PSA = pros-
tate-speciﬁc antigen; SD = standard deviation.
a The last docetaxel dose was deﬁned as the date of the last intravenous administration of docetaxel.
Table 2
Cabazitaxel exposure in patients having completed therapy or withdrawing from the study for any reason.
<70 years (n = 238) 70–74 years (n = 100) P75 years (n = 88) Total (n = 426)
Median number of cabazitaxel cycles [range] 4.0 [1–16] 4.0 [1–12] 4.0 [1–11] 4.0 [1–16]
Dose delay for AEs possibly related to cabazitaxel (%) 14.3 13.0 5.7 12.2
Dose reduction for any cause (%) 18.5 16.0 15.9 17.4
Median relative dose intensity (%) 98.9 98.9 99.1 98.9
AEs = adverse events.
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(26.1%), cabazitaxel becoming commercially available
(18.6%), investigator decision (8.5%) or other reason
(8.6%), Patients who were switched to commercially
available drug continued to be treated until disease pro-
gression or signiﬁcant toxicity but subsequent cycleswere no longer collected in the case report form. A
median of four cycles (range 1–16) of cabazitaxel was
administered within a median duration of 12 weeks. At
the time of analysis (31st August 2011), 36% of patients
aged <70 years, 35% of patients aged 70–74 years and
29% of patients aged P75 years had received six cycles
Table 3
Most common treatment emergent adverse events (classiﬁed by decreased order of all grade toxicities in men aged P75 years).
Toxicity <70 years (n = 421) 70–74 years (n = 180) P75 years (n = 145) Total (n = 746)
All grades Grade P3 All grades Grade P3 All grades Grade P3 All grades Grade P3
Haematological (%)
Neutropenia 17.8 15.0 19.4 16.7 26.2 23.4 19.8 17.0
Anaemia 20.9 5.0 22.8 4.4 22.1 4.1 21.6 4.7
Leukopenia 9.5 6.2 11.7 8.3 12.4 9.7 10.6 7.4
Febrile neutropenia 5.5 5.2 5.6 5.6 5.5 5.5 5.5 5.4
Thrombocytopenia 5.0 1.4 3.9 0.6 4.8 0.7 4.7 1.1
Neutropenic sepsis 1.0 1.0 1.7 1.7 1.4 1.4 1.3 1.3
Non-haematological (%)
Diarrhoea 34.9 3.3 32.2 1.7 36.6 2.8 34.6 2.8
Fatigue 24.5 4.0 27.8 3.3 24.1 5.5 25.2 4.2
Asthenia 13.5 1.4 20.0 4.4 22.8 5.5 16.9 2.9
Nausea 25.4 0 16.7 0.6 19.3 3.4 22.1 0.8
Decreased appetite 12.1 0.5 15.6 1.7 15.2 0.7 13.5 0.8
Vomiting 16.6 1.0 15.6 1.1 10.3 2.1 15.1 1.2
Constipation 13.5 0 12.2 0.6 11.7 0 12.9 0.1
Urinary tract infection 7.8 1.7 5.0 1.1 9.7 2.8 7.5 1.7
Dysgeusia 5.5 0 3.3 0 7.6 0.7 5.8 0.1
Haematuria 6.2 0.5 11.1 2.8 6.9 1.4 7.5 1.2
Back pain 8.8 1.4 5.6 0 6.9 0 7.6 0.8
Peripheral oedema 1.0 0 3.3 0 5.5 0 2.9 0
Bone pain 9.5 1.2 5.0 0.6 4.1 1.4 7.4 1.1
Dyspnoea 4.3 0.7 7.2 1.1 4.1 1.4 5.0 0.9
Alopecia 3.8 0 2.2 0 3.4 0.7 3.4 0.1
Peripheral neuropathy 5.2 0 3.9 0 2.8 0.7 4.4 0.1
Nail disordersa 1.0 0 1.1 0 2.1 0 1.2 0
a Includes nail changes, nail decolouration, nail dystrophy, onychoclasis, onycholysis, onychomadesis.
Table 4
G-CSF use during therapy.
<70 years (n = 421) 70–74 years (n = 180) P75 years (n = 145) Total (n = 746)
G-CSF use at cycle 1 (%) 47.0 57.2 60.0 52.0
Primary prophylaxis 39.2 46.1 50.3 43.0
Therapeutic use 5.5 6.1 6.9 5.9
Primary prophylaxis and therapeutic use 2.4 5.0 2.8 3.1
G-CSF use at any cycle during the trial (%) 58.0 67.8 65.5 61.8
Primary prophylaxis 52.3 58.9 58.6 55.1
Therapeutic use 7.8 9.4 10.3 8.7
Primary prophylaxis and therapeutic use 5.2 7.2 6.2 5.9
G-CSF = granulocyte colony-stimulating factor.
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all groups. The percentage of patients experiencing dose
delays for treatment-emergent AEs (TEAEs) possibly
related to cabazitaxel (<70 years, 14.3%; 70–74 years,
13.0%, P75 years, 5.7%) and dose reductions for any
cause (<70 years, 18%; 70–74 years, 16.0%; P75 years,
15.9%) did not increase with age.
3.3. Safety overview
The overall incidence of TEAEs was similar between
the three groups (<70 years, 88%; 70–74 years 90.5%,
P75 years, 88.3%). Grade P3 toxicities, related or not
to cabazitaxel, occurred in 47% of men aged <70 years,50% of men aged 70–74 years and 56.6% of men aged
P75 years. Treatment discontinuations due to TEAEs
occurred in 13.3% of men aged <70 years, 17.2% of
men aged 70–74 years and 21.4% of men aged
P75 years. Eight patients aged <70 years (1.9%) and
eight patients aged P70 years (2.5%) experienced
TEAEs possibly related to cabazitaxel that led to death.
In seven cases (three aged <70 years, one aged 70–
74 years and three aged P75 years) death was related
to neutropenia or its complications (febrile neutropenia,
neutropenic infection or sepsis), which occurred mainly
at cycle 1 (n = 6) in patients who did not receive G-
CSF prophylaxis (n = 5). In six other cases (four aged
<70 years and two agedP75 years), death was consecu-
Table 5
Predictive factors for grade P3 neutropenia, febrile neutropenia or neutropenic sepsis.
Predictive factor OR (95% CI)b p Value
Univariate analysis
Age (70–74 versus <70 years)a 1.12 (0.75–1.67) 0.578
Age (P75 versus <70 years)a 1.65 (1.11–2.45) 0.014
Cycle 1 versus cycle >1a 6.12 (4.73–7.92) <0.0001
Prior docetaxel cycles (P10 versus <10)a 0.76 (0.55–1.06) 0.107
ECOG performance status (1 versus 0) 0.84 (0.60–1.19) 0.331
ECOG performance status (2 versus 0) 0.68 (0.36–1.29) 0.234
G-CSF prophylaxis at a given cyclea 0.63 (0.45–0.88) 0.007
Time since initial diagnosis (P59.6 versus <59.6 months) 0.96 (0.69–1.34) 0.818
Neutrophils at previous cycle (<4.0 versus P4.0 giga/l)a 2.19 (1.61–2.98) <0.0001
Visceral metastatic site(s) (at least one) 0.91 (0.61–1.35) 0.643
Multivariate analysis
Age (70–74 versus <70 years) 1.08 (0.70–1.64) 0.733
Age (P75 versus <70 years) 1.66 (1.09–2.52) 0.018
Cycle 1 versus cycle >1 5.16 (3.92–6.79) <0.0001
Prior docetaxel cycles (P10 versus <10) 0.77 (0.54–1.09) 0.140
G-CSF prophylaxis at given cycle 0.70 (0.49–0.99) 0.042
Neutrophils at previous cycle (<4.0 versus P4.0 giga/l) 1.73 (1.25–2.39) 0.0008
CI = conﬁdence interval; ECOG = Eastern Cooperative Oncology Group; G-CSF = granulocyte colony-stimulating factor; GEE = generalised
estimating equation; OR = odds ratio.
a Variables retained after initial univariate process (p value 60.25).
b Univariate ORs were estimated via a simple logistic GEE regression. Multivariate ORs were estimated via a multivariate logistic regression
using data from patients with available data for all parameters (n = 732).
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was no concomitant neutropenia, and in ﬁve of the six
cases the patient received prophylactic G-CSF.
3.4. Most common TEAEs
The most common haematological and non-haemato-
logical TEAEs are listed in Table 3. Overall, any grade
diarrhoea (35%), fatigue (25%), nausea (22%), anaemia
(22%) and neutropenia (20%) were the most common
TEAEs. GradeP3 toxicities were mainly haematological
(neutropenia 17%, leukopenia 7%, febrile neutropenia
5% and anaemia 5%). Main non-haematological grade
P3 toxicities were fatigue (4.2%), asthenia (2.9%) and
diarrhoea (2.8%). GradeP3 peripheral neuropathy, alo-
pecia and nail disorders were uncommon (0.1%). No
major diﬀerence between age groups was observed, but
prophylactic use of G-CSFwasmore common in patients
agedP70 years than in younger patients (Table 4).
3.5. Analysis of predictive factors for grade P3
neutropenia and neutropenic complications
In univariate analysis, predictors of gradeP3 neutro-
penia and/or neutropenic complications (febrile neutro-
penia and neutropenic sepsis) were advanced age
(P75 years), ﬁrst cabazitaxel cycle, no G-CSF prophy-
laxis at a given cycle, neutrophil count <4000/mm3
before cabazitaxel injection and less than 10 prior cycles
of docetaxel (Table 5).
Except for the number of prior docetaxel cycles, a
multivariate analysis with backward selection procedureconﬁrmed the predictive value of these factors (Table 5).
First cabazitaxel cycle was associated with a ﬁve-times
increased risk of grade P3 neutropenia and/or neutro-
penic complications (OR 5.16, p < 0.0001), followed by
neutrophil count <4000/mm3 (OR 1.73, p = 0.0008)
and age P75 years (OR 1.66, p = 0.018). Even in the
presence of these factors, prophylaxis with G-CSF at a
given cycle signiﬁcantly reduced the risk of grade P3
neutropenia and/or neutropenic complications by 30%
(OR 0.70, p = 0.04).
4. Discussion
Results and analysis of this large European CUP/
EAP, which included 746 older patients with mCRPC
progressing during or after docetaxel, suggest that cab-
azitaxel has a manageable safety proﬁle. In this popula-
tion of rather ﬁt elderly men (only 10.5% had an ECOG
performance status of 2), dose intensity, dose delays for
AEs possibly related to cabazitaxel and dose reductions
for any cause, in men aged 70–74 years and P75 years,
were similar to those in younger patients. Diarrhoea, the
most common non-haematological AE reported with
cabazitaxel, was usually mild in severity, with grade
P3 occurring in only 2% of patients.
Chemotherapy-associated neutropenia is a particular
concern in the elderly [29]. The EORTC has published
guidelines for the management of neutropenia, including
an algorithm based on evaluation of predisposing fac-
tors, to determine if prophylactic G-CSF should be
oﬀered to the individual patient [27]. Evaluation of the
need for G-CSF should be repeated at each treatment
Table 6
Rates of key adverse events in the TROPIC trial and the European compassionate-use programmes (CUP)/expanded-access programmes (EAP).
Toxicity TROPIC [1] European CUP/EAP
Mitoxantrone (n = 371) Cabazitaxel (n = 371) Cabazitaxel (n = 746)
All grades Grade P3 All grades Grade P3 All grades Grade P3
Haematological (%)
Neutropenia 88 58 94 82 19.8 17.0
Anaemia 81 5 97 11 21.6 4.7
Leukopenia 92 42 96 68 10.6 7.4
Febrile neutropenia – 1 – 8 5.5 5.4
Thrombocytopenia 43 2 47 4 4.7 1.1
Non-haematological (%)
Diarrhoea 11 <1 47 6 34.6 2.8
Fatigue 27 3 37 5 25.2 4.2
Asthenia 12 2 20 5 16.9 2.9
Nausea 23 <1 34 2 22.1 0.8
Vomiting 10 0 23 2 15.1 1.2
Constipation 15 1 20 1 12.9 0.1
Haematuria 4 2 17 2 7.5 1.2
Urinary tract infection 3 1 7 1 7.5 1.7
Bone pain 5 2 5 1 7.4 1.1
Back pain 12 3 16 4 7.6 0.8
Dyspnoea 5 1 12 1 5.0 0.9
Peripheral neuropathy – 1 – 1 4.4 0.1
Alopecia 4.9 0 10 0 3.4 0.1
Nail and nail-bed conditions 4 0 3.5 0 1.2 0
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National Comprehensive Cancer Network (NCCN) and
ASCO [13,14]. Accordingly, prophylactic G-CSF use
was more common in patients aged P70 years in the
European CUP/EAP. In such conditions, haematologi-
cal tolerability of cabazitaxel appeared similar to youn-
ger counterparts.
We conducted a multivariate analysis to identify clin-
ical variables associated with an increased risk of grade
P3 neutropenia and/or neutropenic complications,
according to a cycle-based prediction model developed
by Dranitsaris and colleagues that enables reassessment
of the risk at each additional chemotherapy cycle [28].
Data have shown that the risk of neutropenic complica-
tions is higher at chemotherapy initiation, and decreases
with subsequent cycles [30]. In agreement with the liter-
ature [27], we observed that advanced age (P75 years)
was an independent predictor of grade P3 neutropenia
and/or neutropenic complications. The ﬁnding that ﬁrst
cabazitaxel cycle is associated with a ﬁvefold higher risk
of developing gradeP3 neutropenia and/or neutropenic
complications, especially when there is a neutrophil
count <4000/mm3 before cabazitaxel injection, is a
strong rationale for using prophylactic G-CSF in older
patients with advanced mCRPC. This is in agreement
with a pilot analysis of predictive factors for neutrope-
nia in the Italian EAP, which found that the use of pro-
phylactic G-CSF reduced the risk of grade 3
neutropenia sevenfold [31].
The results of this interim analysis extend the knowl-
edge of the safety proﬁle reported in TROPIC to asetting that is more reﬂective of everyday clinical prac-
tice, especially for senior adults [1]. Table 6 lists the rates
of key haematological and non-haematological AEs in
the TROPIC trial and, from this preliminary European
CUP/EAP analysis. This table is provided for informa-
tion only, since both studies cannot be compared for
several reasons: (1) It is possible that the patients
included in the TROPIC trial and CUP/EAP had a dif-
ferent disease burden, (2) TROPIC was conducted in 26
countries in Europe, North America, Latin America,
India, Asia and South Africa, and it appears that some
centres were not suﬃciently experienced in monitoring
and managing the toxicities of chemotherapy.
(3) Haematology was monitored on a weekly basis in
TROPIC while it was collected before each injection in
the European CUP/EAP in order to reﬂect real-life
practice (4) Prophylactic G-CSF at the ﬁrst cabazitaxel
cycle was not allowed in TROPIC (it was allowed at
physicians’ discretion after ﬁrst occurrence of either neu-
tropenia lasting 7 days or more or neutropenia compli-
cated by fever or infection) [1] while in the European
CUP/EAP, prophylactic G-CSF was allowed from the
ﬁrst cycle, as per ASCO and EORTC guidelines
[14–27]. The lower rate of AEs in this large European
cohort may also be partly attributed to the physician
and nurse awareness programme for proactive manage-
ment of AEs related to cabazitaxel which was systemat-
ically implemented in all CUP/EAP centres. It has been
shown that the optimal oncological care of older men
with prostate cancer, including eﬀective prevention,
early reporting, and management of the disease and
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improve quality of life, and reduce depressive symptoms
and treatment discontinuations [32,33]. The TROPIC
centres in France incorporated a number of pro-active
measures—analysis of outcomes of the 90 patients
enrolled in these centres evidenced a lower discontinua-
tion rate due to AEs compared with the overall TRO-
PIC population and no death associated with therapy,
possibly contributing to a greater survival beneﬁt [23].
The importance of proactive AE management was also
conﬁrmed by results of the German CUP, which
included patients with more advanced and heavily pre-
treated disease than in the TROPIC trial [24]. Grade
P3 haematological toxicity and febrile neutropenia
were observed in only 21% and 2% of patients in the
German CUP, respectively. Patients had been inten-
sively counselled about symptoms necessitating early
readmission to hospital, and informed about the proba-
bility of diarrhoea and the initial management measures
to be implemented at home. However, there is still room
for improvement in order to further decrease the 2.1%
death rate, mainly due to infections and/or neutropenic
complications, reported in this CUP/EAP. Administra-
tion of chemotherapy in well-trained centres, adequate
patient selection, guidance and information are all
important measures which should help to achieve this
goal [34].
Accumulating evidence from CUPs/EAPs indicate
that real-world toxicity of cabazitaxel is less than that
experienced in the TROPIC trial and is manageable with
appropriate prophylactic and supportive care measures,
even in older patients. The importance of such measures
should not be underestimated, especially in older men
heavily pretreated for advanced prostate cancer who
may be vulnerable to treatment complications or side-
eﬀects.
5. Conclusion
The preliminary results of this large European CUP/
EAP show that the AE proﬁle is manageable in routine
practice in both younger (<70 years) and elderly patients
(70–74 years and P75 years) with mCRPC. Prophylac-
tic G-CSF use was more common in older men, as nor-
mally recommended by international guidelines—in
such conditions, haematological tolerability of cabazit-
axel appears similar to younger counterparts. In multi-
variate analysis, ageP 75 years, treatment cycle 1 and
a neutrophil count <4000/mm3 before cabazitaxel injec-
tion were associated with an increased risk of developing
grade P3 neutropenia and/or neutropenic complica-
tions. In the presence of these factors, G-CSF
signiﬁcantly reduced this risk by 30%. These results
underline the importance of adequate proactive manage-
ment of AEs, including G-CSF prophylaxis, and patient
follow up, to improve the tolerability of cabazitaxel in
the real-world setting. These supportive care measuresshould ultimately contribute to improved patient
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